Latest news with #CSTL
Yahoo
16 hours ago
- Business
- Yahoo
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of the conference call can be accessed here: or via the webcast link on the Investor Relations page of the Company's website: Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call. To access the live conference call via phone, please dial 1 833 470 1428 from the United States, at least 10 minutes prior to the start of the call, using the access code 638217. International dial-in numbers are available here: please use the same access code above to join the call. There will be a brief Question and Answer session following management commentary. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
Yahoo
30-05-2025
- Business
- Yahoo
Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025
Castle Biosciences, Inc. (NASDAQ:CSTL) has announced new data to be presented at ASCO 2025 showing that its DecisionDx-Melanoma test is linked to a 32% reduction in mortality risk for patients with cutaneous melanoma compared to those who were untested. The findings come from the largest real-world study of gene expression profile testing in melanoma, analyzing over 13,500 patients in collaboration with the National Cancer Institute's SEER Program Registries. A doctor using a microscope in a lab, conducting research on cancer treatments. Castle Biosciences, Inc. (NASDAQ:CSTL)'s Dx-Melanoma test, which evaluates a 31-gene expression profile, offers significant, independent risk stratification beyond traditional AJCC staging, helping clinicians make more precise, personalized treatment decisions. According to lead author Dr. Merve Hasanov, the test enables more accurate mortality risk predictions based on a patient's unique tumor biology, allowing for better-tailored care. These results further affirm the test's association with improved patient survival and its potential to guide risk-aligned management strategies. DecisionDx-Melanoma has been ordered more than 200,000 times and is supported by over 50 peer-reviewed studies, underscoring its growing role in melanoma care and its impact on patient outcomes. While we acknowledge the potential of CSTL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CSTL and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
22-04-2025
- Business
- Business Upturn
Clean Science and Technology invests Rs 50 crore in subsidiary Clean Fino-Chem
By Aditya Bhagchandani Published on April 22, 2025, 18:04 IST Clean Science and Technology Limited (CSTL) has infused fresh capital into its wholly owned subsidiary, Clean Fino-Chem Limited (CFCL), by subscribing to additional equity shares worth Rs 50 crore. The investment is aimed at supporting upcoming projects within CFCL's operations in the specialty chemicals sector. As per the company's regulatory filing dated April 22, 2025, CSTL subscribed to 8,36,121 equity shares of face value Rs 10 each at a premium of Rs 588 per share. The total transaction value stands at Rs 50,00,00,358. The shares have been allotted under a rights issue and will rank pari passu with existing equity shares. The company clarified that the transaction qualifies as a related party deal since CFCL is a wholly owned subsidiary. However, it added that the investment has been made at arm's length and does not involve any undue interest from the promoter group beyond the ownership structure. Clean Fino-Chem Limited, incorporated in March 2022, operates in the specialty chemicals industry and focuses on manufacturing and sales in India. The additional capital raised through this transaction will primarily be used to fund CFCL's ongoing and future projects. The company reported a turnover of Rs 1.92 crore for FY24, marking its initial operations phase. The transaction reinforces CSTL's commitment to expanding its capabilities and presence in the specialty chemicals space, with a focus on vertical integration and capacity building through its subsidiaries. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Yahoo
28-02-2025
- Business
- Yahoo
Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
Fourth Quarter Revenue: $86.3 million, a 31% increase over Q4 2023. Full Year Revenue 2024: $332.1 million, a 51% increase over 2023. Total Test Report Volume Growth 2024: 36% increase compared to 2023. Cash, Cash Equivalents, and Marketable Securities: $293.1 million as of December 31, 2024. Gross Margin Q4 2024: 76.2% compared to 77.8% in Q4 2023. Full Year Gross Margin 2024: 78.5% compared to 75.4% in 2023. Net Income Q4 2024: $9.6 million compared to a net loss of $2.6 million in Q4 2023. Full Year Net Income 2024: $18.2 million compared to a net loss of $57.5 million in 2023. Diluted Earnings Per Share Q4 2024: $0.32 compared to a diluted loss per share of $0.10 in Q4 2023. Full Year Diluted Earnings Per Share 2024: $0.62 compared to a diluted loss per share of $2.14 in 2023. Adjusted EBITDA Q4 2024: $21.3 million compared to $9.4 million in Q4 2023. Full Year Adjusted EBITDA 2024: $75 million compared to a negative $4.4 million in 2023. Net Cash Provided by Operating Activities 2024: $64.9 million. DecisionDx-Melanoma Test Reports 2024: 36,008, an 8% increase over 2023. DecisionDx-SCC Test Reports 2024: 16,348, a 43% increase over 2023. TissueCypher Test Reports 2024: 20,956, a 130% increase over 2023. Warning! GuruFocus has detected 2 Warning Sign with CSTL. Release Date: February 27, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Castle Biosciences Inc (NASDAQ:CSTL) reported a 51% year-over-year revenue growth, reaching $332.1 million for the full year 2024. The company achieved a 36% increase in total test report volume in 2024 compared to 2023. Castle Biosciences Inc (NASDAQ:CSTL) ended 2024 with $293.1 million in cash, cash equivalents, and marketable investment securities, a $50 million increase over the previous year. The TissueCypher test saw a 130% growth in test report volume in 2024, with positive reception from the gastroenterology community. Castle Biosciences Inc (NASDAQ:CSTL) achieved a net income of $18.2 million for 2024, compared to a net loss of $57.5 million in 2023. The DecisionDx-SCC test faces potential noncoverage by Medicare starting April 24, 2025, which could impact revenue. Gross margin decreased slightly in the fourth quarter of 2024 to 76.2% from 77.8% in the same period of 2023. The company anticipates a decrease in IDgenetix test report volumes and net revenues in 2025 due to market changes. Castle Biosciences Inc (NASDAQ:CSTL) expects typical seasonality to affect the first quarter of 2025, potentially leading to flat or slightly down volumes compared to the fourth quarter of 2024. The company faces challenges in expanding the use of DecisionDx-Melanoma in academic centers due to the absence of guideline inclusion. Q: In our checks, we have noticed that private dermatologists usually prefer DecisionDx-Melanoma, but dermatologists in academic centers are still hesitant to order more broadly before guideline inclusion. Do you agree? How should we think about the opportunity in the absence of guideline updates? A: Derek Maetzold, CEO: The feedback from your interviews seems contrary to the 1,800 new first-time ordering clinicians in 2024. While some clinicians may have settled into a sweet spot, we saw substantial growth in new first-time ordering clinicians. Outside of a few NCCN centers, we don't hear much feedback regarding guideline inclusion affecting personal decisions. Q: When should we expect reimbursement updates for the atopic dermatitis gene expression profile test planned for launch by the end of 2025? A: Derek Maetzold, CEO: Assuming successful validation study results, we aim to launch in late 2025. The reimbursement strategy will be developed over the next several quarters, focusing on patient outcomes and fair reimbursement. Material revenue is not expected until 2028 or 2029. Q: On TissueCypher and getting the New York State Department of Health approval, what percentage of the addressable market does New York State represent? A: Derek Maetzold, CEO: I don't have the exact percentage, but demographically, it should be similar to New York's population percentage of the overall US population. Q: What's the commercial strategy for DecisionDx-SCC while resolving reimbursement issues? Will you continue to offer the test? A: Derek Maetzold, CEO: If we lose coverage, it will be disappointing for patient care. If there's a short-term path to regaining reimbursement, we may continue offering the test. If not, we'll balance shareholder impact and patient needs. We don't plan to remove the test completely. Q: Regarding strategic opportunities with capital allocation, should we consider existing or new verticals? A: Derek Maetzold, CEO: We focus on investing in current commercial efforts and exploring external opportunities. While it's easier to expand within current verticals, we're open to new areas if they offer strong upside. Q: With SCC likely disappearing from the topline, how should we think about adjusted EBITDA for 2025? A: Frank Stokes, CFO: We expect to remain adjusted EBITDA positive for the year, but haven't provided specific guidance on the scale. Q: Is there any residual from non-Medicare payers and private pay on SCC? A: Frank Stokes, CFO: There is not significant private or commercial payment for SCC; it's still very early. Q: How should we model SG&A for 2025? Is the salesforce expenditure increasing? A: Frank Stokes, CFO: We've expanded the TissueCypher salesforce, reflected in Q4 numbers. We'll continue to invest in the salesforce as we see penetration, but no sweeping changes are expected. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
